Patient groups and practitioners have raised concerns about a new Cigna policy that offers a $500 pre-paid medical debit card to patients if they switch from a biologic product for multiple rheumatic diseases to a Cigna-preferred drug. The policy follows Cigna’s removal of the drug from its preferred drug list and encourages patients to switch to drugs for nonmedical reasons. Patients and practitioners have called the $500 debit card coercive during the economic uncertainty caused by the COVID-19 pandemic and expressed concerns that it could result in nonmedical switching. Read more here and here.
Last Updated on April 29, 2021 by Aimed Alliance
